Anopheles gambiae

Anopheles gambiae
Name	Anopheles gambiae
Genus	Anopheles
Species	gambiae
Authority	Giles, 1902

Anopheles gambiae. It is a principal vector for the transmission of the deadly Plasmodium falciparum parasite, the causative agent of the most severe form of human malaria. This mosquito species is a member of the Anopheles gambiae complex, a group of at least seven morphologically indistinguishable sibling species, and is predominantly found across Sub-Saharan Africa. Its profound efficiency in transmitting the disease has made it a central focus of global public health initiatives and extensive scientific research aimed at curbing the immense burden of malaria.

Taxonomy and classification

The species was first formally described by the British entomologist Giles in 1902. It is the nominal species of the Anopheles gambiae complex, a group whose intricate speciation was elucidated through modern genetic techniques by researchers at institutions like the University of Notre Dame and the Wellcome Trust Sanger Institute. Key members of this complex include Anopheles arabiensis and Anopheles coluzzii, the latter having been recognized as a distinct species following genomic studies. The complex falls under the larger Anopheles genus within the family Culicidae.

Morphology and identification

Adult mosquitoes are characterized by their slender bodies, with females possessing long, piercing mouthparts, or proboscis, adapted for blood-feeding. They are typically identified by specific morphological features, including the pattern of pale and dark scales on their wings and the structure of their eggs, which have distinct floats. Differentiation from sibling species within the complex, such as Anopheles merus, often requires molecular analysis of genetic markers or examination of chromosome banding patterns, as pioneered by scientists like Mario Coluzzi.

Distribution and habitat

This mosquito is extensively distributed throughout Sub-Saharan Africa, with its range closely overlapping regions of high malaria endemicity, including countries like Nigeria, the Democratic Republic of the Congo, and Tanzania. It thrives in a variety of aquatic habitats for larval development, preferring sunlit, temporary freshwater collections such as puddles, rice fields, and the edges of streams. Its distribution can be influenced by climatic factors and human activities like irrigation projects, which can create new breeding sites.

Life cycle and behavior

The life cycle involves complete metamorphosis, progressing from aquatic larvae and pupae to terrestrial adults. Female mosquitoes are anautogenous, requiring a blood meal from a host, typically humans, to develop their eggs, a behavior that drives their role as disease vectors. They are primarily nocturnal and endophagic, feeding indoors, and often exhibit endophily, resting inside dwellings after feeding, which increases human contact. Key research on their behavior has been conducted at facilities like the Ifakara Health Institute.

Role in malaria transmission

It is the most efficient vector for Plasmodium falciparum in Africa. The parasite undergoes a complex developmental cycle within the mosquito, involving stages in the midgut and salivary glands. The mosquito's strong preference for human blood, known as anthropophily, and its high susceptibility to the parasite make it exceptionally effective at transmission. This efficiency has been a major factor in the persistence of malaria as a leading cause of mortality in Africa, particularly among children under five, as tracked by the World Health Organization.

Control and prevention strategies

Control efforts are multifaceted and historically have included widespread use of insecticide-treated nets and indoor residual spraying with compounds like DDT and newer pyrethroids. The emergence of insecticide resistance has driven research into alternative methods, such as larval source management and genetic modification strategies explored by projects like Target Malaria. Other approaches include the use of artemisinin-based combination therapy to treat human infection and the deployment of the RTS,S malaria vaccine developed by GlaxoSmithKline and the PATH Malaria Vaccine Initiative.

gambiae Category:Disease vectors Category:Insects of Africa